TP53 and diffuse large B-cell lymphoma: Many prognostic markers have been considered, such as MYC gene alterations, which characterize from 5% to 15% of de novo DLBCL and confer a worse prognosis and higher risk of central nervous system involvement [36], as well as TP53 mutation, Epstein–Barr virus infection, CD5 expression, CD30 expression, BCL2 rearrangement or expression, MHC class II expression, and others [37,38,39,40,41,42,43,44,45,46,47,48], each presenting with contradicting data regarding their prognostic relevance.